Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

Authors:
Publisher website
Google Scholar
Abstract
An inhibitor of human liver glycogen phosphorylase a (HLGPa) has been identified and characterized in vitro and in vivo . This substance, [R-(R*,S*)]-5-chloro- N -[3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide (CP-91149), inhibited HLGPa with an IC 50 of 0.13 μM in the presence of 7.5 mM glucose. CP-91149 resembles caffeine, a known allosteric phosphorylase inhibitor, in that it is 5- to 10-fold less potent in the absence of glucose. Further analysis, however, suggests that CP-91149 and caffeine are kinetically distinct. Functionally, CP-91149 inhibited glucagon-stimulated glycogenolysis in isolated rat hepatocytes ( P < 0.05 at 10–100 μM) and in primary human hepatocytes (2.1 μM IC 50 ). In vivo , oral administration of CP-91149 to diabetic ob/ob mice at 25–50 mg/kg resulted in rapid (3 h) glucose lowering by 100–120 mg/dl ( P < 0.001) without producing hypoglycemia. Further, CP-91149 treatment did not lower glucose levels in normoglycemic, nondiabetic mice. In ob/ob mice pretreated with 14 C-glucose to label liver glycogen, CP-91149 administration reduced 14 C-glycogen breakdown, confirming that glucose lowering resulted from inhibition of glycogenolysis in vivo. These findings support the use of CP-91149 in investigating glycogenolytic versus gluconeogenic flux in hepatic glucose production, and they demonstrate that glycogenolysis inhibitors may be useful in the treatment of type 2 diabetes.

This publication has 42 references indexed in Scilit: